Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

947567

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	PrescQIPP
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assurances they have received from PresQIPP that when providing guidance to Clinical Commissioning Groups on commissioning decisions it has taken the views of patient stakeholders into account.
tabling member printed	Lord Hunt of Kings Heath
uin	HL9849
answer	answer is ministerial correction date of answer 26/07/2018 answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9847 HL9848 question first answered 26/07/2018 12:46:36 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf title Items which should not routinely be prescribed
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

947098

registered interest
date	23/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will ensure that the appropriate funds will be made available when an endocrinologist has prescribed liothyronine (T3) for an NHS patient.
tabling member printed	Lord Hunt of Kings Heath
uin	HL9788
answer	answer is ministerial correction date of answer 25/07/2018 answer text <p>It is the responsibility of clinical commissioning groups (CCGs) to make decisions on funding in their local areas. NHS England expects CCGs to have due regard to <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017. A copy of the guidance is attached. The guidance is clear that liothyronine can and should be prescribed by an endocrinologist when it is clinically appropriate to do so, providing the funding has been agreed with the commissioner.</p><p>If an individual cannot get a medicine their prescriber feels is the most appropriate, under local commissioning arrangements, the prescriber can make an Individual Funding Request on behalf of the patient for that medicine to be provided.</p> answering member printed Lord O'Shaughnessy question first answered 25/07/2018 15:53:32 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name items-which-should-not-routinely-be-prescribed-in-pc-ccg-guidance.pdf title Items which should not routinely be prescribed
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

947100

registered interest
date	23/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will take steps to withdraw PrescQIPP guidance to Clinical Commissioning Groups in the East of England on prescribing liothyronine (T3) as it has not been updated to reflect current national guidelines.
tabling member printed	Lord Hunt of Kings Heath
uin	HL9790
answer	answer is ministerial correction date of answer 25/07/2018 answer text <p>PrescQIPP is an independent social enterprise and any decision to withdraw this guidance is a matter for PrescQIPP.</p><p>Clinical commissioning groups (CCGs) are responsible for deciding whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> answering member printed Lord O'Shaughnessy question first answered 25/07/2018 15:53:50 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name items-which-should-not-routinely-be-prescribed-in-pc-ccg-guidance.pdf title Items which should not routinely be prescribed
tabling member	2024 label Biography information for Lord Hunt of Kings Heath